Evolving role of hepatic resection for metastatic urologic malignancies

John B. Hamner, Mustafa Raoof, Sinziana Dumitra, Hans F. Schoellhammer, Carly Crowder, Philip H.G. Ituarte, Joseph Kim, Gagandeep Singh

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Liver resection for noncolorectal, nonneuroendocrine metastases remains controversial. Here, we evaluate a single institutional experience with hepatic resection for metastatic urologic malignancies. A single-institution review of patients who underwent hepatic resection for metastatic urologic tumors between the years of 2000 and 2013 was performed. Patient charts were analyzed for pathologic data and perioperative outcomes including short- and long-term morbidity, mortality, and overall and disease-free survival. Eleven patients were identified who underwent hepatic resection for metastatic urologic malignancy. The mean age was 63.5 years. All patients had an R0 resection. There were three major complications. Mean length of stay was 6.5 days and there was no 90-day mortality. Three patients have died of recurrent disease at an average of 11.2 months from resection to death. The remaining patients are still alive during a mean follow-up of 31.5 months. Five-year overall and disease-free survival was 50 and 21 months, respectively. Hepatic resection for metastatic urologic tumors is safe with low morbidity and mortality and durable long-term survival can be achieved. Liver resection for isolated hepatic disease should be considered for this rare metastatic disease to the liver.

Original languageEnglish
Pages (from-to)628-632
Number of pages5
JournalAmerican Surgeon
Volume83
Issue number6
StatePublished - Jun 2017

ASJC Scopus subject areas

  • Surgery

Fingerprint

Dive into the research topics of 'Evolving role of hepatic resection for metastatic urologic malignancies'. Together they form a unique fingerprint.

Cite this